Featured News

Boston Business Journal

April 9, 2025

Woburn biotech takes needles out of GLP-1 delivery with patch

Boston Business Journal

ENDPOINTS NEWS

March 25, 2026

Exclusive: Microneedle vaccine patch company raises $50M for pivot to GLP-1 delivery

Endpoints News

Drug Delivery

June 23, 2025

Vaxess study highlights GLP-1 delivery with microarray patch

Drug Delivery Business

Announcements

June 8, 2026

Terrestrial Presents Data on Needle-Free Microarray Patch for Codelivery of Amylin Analog and GLP-1 Therapy Without Coformulation

Terrestrial

June 4, 2026

Terrestrial Awarded $2.2M in Massachusetts State Grants to Scale Microarray Patch Manufacturing

Terrestrial

March 26, 2026

Terrestrial Announces $50M Series C and Rebrands from Vaxess Technologies

Terrestrial

January 5, 2026

Vaxess 2025 Year in Review

Terrestrial

December 4, 2025

Vaxess Human Factors Study Shows Patient Preference for Patch-Based GLP-1 Delivery Over Injections

Terrestrial

September 17, 2025

Vaxess Announces Vice President of Manufacturing

Terrestrial

June 23, 2025

Vaxess Presents Data on Development of Needle-Free, Self-Applied Microarray Patch for GLP-1 Delivery

Terrestrial

April 9, 2025

Vaxess Announces $9M in Funding for Microarray Drug Delivery Platform

Terrestrial

January 6, 2025

Vaxess 2024 Year in Review

Terrestrial

October 1, 2024

Vaxess Receives National Institutes of Health Grant to Explore Administering Type 2 Diabetes Treatment via the MIMIX™ Transdermal Patch Platform

Terrestrial

August 12, 2024

Vaxess Adds RA Capital Management Founding Partner Peter Kolchinsky to Board of Directors

Terrestrial

May 22, 2024

Vaxess Announces $12M in Funding

Terrestrial